Wednesday , October 18 2017
Home / Letter From The Editor / Editor’s Note, DCMS #222

Editor’s Note, DCMS #222

There is one conflict that consistently recurs in healthcare. This conflict is between the use of newer, more expensive medications and older cheaper ones. As we have added new classes of drugs in recent years, this conflict is showing up often in diabetes treatment . The newest drugs are very expensive and, in many instances, the insurance companies will not pay for the medication till years after it is on the market. In addition, many of these newer drugs cannot even claim that their results are any better than the 20-30 year old generic meds. A good example of this is the sulfonylureas. The medications can deliver a 1-2% decrease in A1c values for not more than five dollars a month. This often causes prescribers to go to these inexpensive meds for their patients. However, if you check out this week’s Homerun Slides you will see that the cost of the medication is not really representative of the entire cost of using these insulin secretagogues.

Our Clinical Text looks at specific circumstances that can make glucose control difficult, and our Disaster Averted addresses the problem that can arise when a patient goes from a syringe to a pen. Our Mastery In Minutes video will give you a few more tips for your patients on keeping their New Year’s diet resolutions.